Actos Decision Statement: $9 Billion Decision on Eli Lilly and Takeda Pharmaceuticals

On Monday, April 7, a federal court jury in Louisiana decided that Takeda Pharmaceuticals and Eli Lilly hid the risks of bladder cancer from the diabetes drug, Actos. Takeda was ordered to pay $6 billion and Eli Lilly was ordered to pay $3 billion. 

Actos is used to treat Type 2 diabetes for patients who cannot control the symptoms by exercise and diet alone. Although Motley Rice did not represent the plaintiffs in this case, Motley Rice attorneys represent numerous Actos clients and are reviewing new potential Actos claims.

Medical attorney Kimberly Barone Baden said, “We are very pleased with this verdict. The jury found Takeda and Eli Lilly hid the risks of developing bladder cancer and sold a drug to consumers that they knew could cause bladder cancer. It is no coincidence that thousands of cases are filed in the Louisiana MDL and in Cook County, Illinois (where Eli Lilly is headquartered) by people who developed bladder cancer, a life-changing medical diagnosis, after using Actos.” 

Read more about the decision:

• Wall Street Journal: Takeda, Lilly Ordered to Pay $9 Billion in Diabetes-Drug Case

• Bloomberg: Takeda, Lilly Jury Awards $9 Billion Over Actos Risks

* Please remember that every case is different. Any result we achieve for one client in one matter does not necessarily indicate similar results can be obtained for other clients.